Oliver Sartor MD
Director of the Radiopharmaceutical Trials, Chief of the Genitourinary Cancer Malignancy Group, Mayo Clinic, Rochester, MinnesotaDr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, led or co-led multiple national and international clinical studies, including four phase III studies pivotal for FDA approval (Quadramet, Xofigo, Pluvicto, and Jevtana). He has lectured widely, and at last count has given invited lectures in 33 countries.
He has served as the past Chairman of the Department of Defense Prostate Cancer Integration Panel, is past Editor-in-Chief of the peer-reviewed journal Clinical Genitourinary Cancer, and is the Medical Oncology Chair of the GU committee of NRG, a national cancer research group. He is also a past member of the National Cancer Institute Board of Scientific Counselors (Clinical Sciences and Epidemiology).
Disclosures
CONSULTANT: Advanced Accelerator Applications (AAA), Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janssen, Merck, Moyvant, Myriad, Noria Therapeutics, Inc., Novartis, Noxopharm, Progenics, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix, Theragnostics.
Grant/Research Support: Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen, Lantheus, Merck, Progenics, Tenebio.
Recent Contributions to PracticeUpdate:
- Efficacy and Safety of Abiraterone Acetate Plus Prednisone vs Cabazitaxel as a Subsequent Treatment After First-Line Docetaxel in mCRPC
- Ultra-Hypofractionated vs Conventionally Fractionated Radiotherapy for Prostate Cancer
- Androgen Deprivation Therapy and Diagnosis of Dementia in Men With Prostate Cancer
- Pembrolizumab in Patients With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
- Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate
- Efficacy of Radium-223 in Bone-Metastatic Castration-Resistant Prostate Cancer With and Without Homologous Repair Gene Defects
- Enzalutamide With Standard Therapy in Metastatic Prostate Cancer
- Apalutamide for Metastatic Castration-Sensitive Prostate Cancer
- Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality
- Improving Clinical Trial Design for Prostate Cancer